UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting DNA repair and replication stress in the treatment of ovarian cancer

International journal of clinical oncology, 2017-08, Vol.22 (4), p.619-628

Murai, Junko

2017

Volltextzugriff (PDF)

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

Pharmacology & therapeutics (Oxford), 2019-09, Vol.201, p.94-102

2019

Volltextzugriff (PDF)

Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes

Cancer science, 2022-09, Vol.113 (9), p.2943-2951

2022

Volltextzugriff (PDF)

Schlafen 11, a crucial determinant of sensitivity to DNA damaging agents ~basic and clinic

Fujita Medical Journal, 2022, Vol.8(Supplement), pp.10-10

Murai, Junko

2022

Volltextzugriff (PDF)

The evolving landscape of predictive biomarkers of response to PARP inhibitors

The Journal of clinical investigation, 2018-05, Vol.128 (5), p.1727-1730

2018

Volltextzugriff (PDF)

PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers

Annual review of cancer biology, 2019-03, Vol.3 (1), p.131-150

2019

Volltextzugriff (PDF)

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Cancer research (Chicago, Ill.), 2012-11, Vol.72 (21), p.5588-5599

2012

Volltextzugriff (PDF)

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Nature medicine, 2017-04, Vol.23 (4), p.461-471

2017

Volltextzugriff (PDF)

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

Oncogene, 2020-08, Vol.39 (33), p.5520-5535

2020

Volltextzugriff (PDF)

Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1

Cancer research (Chicago, Ill.), 2019-05, Vol.79 (10), p.2460-2461

2019

Volltextzugriff (PDF)

SLFN11 Blocks Stressed Replication Forks Independently of ATR

Molecular cell, 2018-02, Vol.69 (3), p.371-384.e6

2018

Volltextzugriff (PDF)

Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq

Virchows Archiv : an international journal of pathology, 2021-03, Vol.478 (3), p.569-579

2021

Volltextzugriff (PDF)

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors

Clinical cancer research, 2018-04, Vol.24 (8), p.1944-1953

2018

Volltextzugriff (PDF)

SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243

Cancer research (Chicago, Ill.), 2021-06, Vol.81 (11), p.3067-3078

2021

Volltextzugriff (PDF)

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1694-1704

2018

Volltextzugriff (PDF)

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress

Cell reports (Cambridge), 2020-03, Vol.30 (12), p.4137-4151.e6

2020

Volltextzugriff (PDF)

Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel

Molecular cancer therapeutics, 2014-01, Vol.13 (1), p.214-220

2014

Volltextzugriff (PDF)

De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma

Scientific reports, 2021-06, Vol.11 (1), p.13474-13474, Article 13474

2021

Volltextzugriff (PDF)

PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage

Nucleic acids research, 2014-04, Vol.42 (7), p.4435-4449

2014

Volltextzugriff (PDF)

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development

PloS one, 2021-01, Vol.16 (1), p.e0237554

2021

Volltextzugriff (PDF)

Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy

Cancer science, 2022-02, Vol.113 (2), p.784-795

2022

Volltextzugriff (PDF)

Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells

eLife, 2023-07, Vol.12

2023

Volltextzugriff (PDF)

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8), p.1173-1174

2023

Volltextzugriff (PDF)

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma

Clinical cancer research, 2015-09, Vol.21 (18), p.4184-4193

2015

Volltextzugriff (PDF)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

BMC cancer, 2020-11, Vol.20 (1), p.1123-1123, Article 1123

2020

Volltextzugriff (PDF)

1 – 25 von 220

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(196)

Publikationsform

Sprache

Englisch
(190)
Japanisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting DNA repair and replication stress in the treatment of ovarian cancer

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes

Schlafen 11, a crucial determinant of sensitivity to DNA damaging agents ~basic and clinic

The evolving landscape of predictive biomarkers of response to PARP inhibitors

PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1

SLFN11 Blocks Stressed Replication Forks Independently of ATR

Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors

SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress

Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel

De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma

PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development

Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy

Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Suchergebnisse filtern